01—Abstract
Summary
Summary of the 8-K filed May 14, 2025. Cited figures are marked; the original filing is the authoritative source.
On May 11, 2025, Incyte Corporation entered into a settlement agreement with Novartis Pharma AG resolving litigation Novartis initiated over the duration of royalty payments Incyte owes under their Collaboration and License Agreement dated November 24, 2009, as amended.
As of March 31, 2025, Incyte had approximately $537.1 milliona of accrued royalties related to the dispute, included in accrued and other current liabilities on its condensed consolidated balance sheet. Under the settlement, Incyte agreed to pay Novartis $280.0 million to resolve disputed royalties on U.S. net sales of JAKAFI through December 31, 2024. The parties also agreed to reduce by 50% the royalty rate on future U.S. JAKAFI net sales beginning January 1, 2025, for a period defined in the settlement agreement.
The reduced royalty for the quarter ended March 31, 2025 is approximately $14.9 millionb. The filing states that the $242.2 million difference between the total accrued royalties and the amount to be paid to Novartis will be recorded in Incyte's condensed consolidated statement of operations for the quarter ending June 30, 2025. This recognition is a one-time item in the second quarter of 2025 that investors should weigh when assessing near-term reported results.
02—Key points
Key Highlights
- Settlement agreement dated May 11, 2025 with Novartis Pharma AG resolves litigation over the duration of royalty payments under the 2009 Collaboration and License Agreement, as amended.
- Approximately $537.1 million of accrued royalties related to the dispute was recorded as of March 31, 2025, in accrued and other current liabilities.
- Incyte agreed to pay Novartis $280.0 million to settle disputed royalties on U.S. JAKAFI net sales through December 31, 2024.
- The royalty rate on future U.S. JAKAFI net sales is reduced by 50% beginning January 1, 2025, for a period defined in the settlement agreement.
- The reduced royalty payable for the quarter ended March 31, 2025 is approximately $14.9 million.
- A $242.2 million difference between accrued royalties and the settlement payment will be recorded in the statement of operations for the quarter ending June 30, 2025.
- The filing is made under Item 8.01 (Other Events) and does not describe any change to financial guidance.
03—Questions
Frequently Asked Questions
What is the settlement between Incyte and Novartis about?
The settlement resolves litigation Novartis initiated concerning how long Incyte must keep paying royalties under their Collaboration and License Agreement dated November 24, 2009, as amended. The royalties relate to net sales of JAKAFI in the United States.
How much is Incyte paying Novartis under the settlement?
Incyte agreed to pay Novartis $280.0 million to settle disputed royalties on U.S. JAKAFI net sales through December 31, 2024.
How will the settlement affect Incyte's financial results?
Incyte had approximately $537.1 million of accrued royalties related to the dispute as of March 31, 2025. The filing states that the $242.2 million difference between that accrual and the settlement payment will be recorded in the statement of operations for the quarter ending June 30, 2025.
Does the settlement change future royalty payments to Novartis?
Yes. The parties agreed to reduce the royalty rate on future U.S. JAKAFI net sales by 50%, beginning January 1, 2025, for a period defined in the settlement agreement. The reduced royalty for the quarter ended March 31, 2025 is approximately $14.9 million.
04—Continue